Altimmune Under Legal Scrutiny Following Controversial Phase 2b Trial Results for Pemvidutide

Altimmune Faces Legal Scrutiny Over Phase 2b Trial Results

Altimmune, Inc., a biotechnology company specializing in immune therapies, is currently under investigation due to allegations stemming from its recently concluded IMPACT Phase 2b MASH trial for Pemvidutide. The trial, aimed at evaluating the drug's efficacy in fibrosis reduction, has come under fire for potentially misleading representations of its results. Investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, are now encouraged to consider their legal options, with a key deadline of October 6, 2025, approaching for those interested in joining a class action lawsuit.

The allegations against Altimmune suggest that the company did not meet crucial statistical benchmarks related to fibrosis reduction, which may have misled investors regarding the effectiveness of Pemvidutide. Reports indicate that the trial results fell short of expectations, particularly concerning the primary endpoint of reducing fibrosis. The unexpected high placebo response in the trial further complicated the outcome, leading to claims that Altimmune had artificially inflated expectations prior to the trial's conclusion. As a result, the company saw a sharp decline in its stock price, dropping from $7.71 to $3.61 in a single day, marking a staggering 53.2% decrease. This drastic fall has prompted major legal firms like Rosen Law Firm and Faruqi & Faruqi, LLP to step in, urging affected investors to explore their legal rights.

Rosen Law Firm highlights the importance of selecting experienced legal counsel in securities class actions, drawing attention to its successful track record in recovering substantial settlements for investors. The firm emphasizes that those affected by Altimmune's alleged misrepresentations may be eligible for compensation without the burden of upfront fees due to contingency arrangements. Meanwhile, Faruqi & Faruqi is actively investigating potential claims against Altimmune, urging investors to discuss their options with legal representatives promptly. The ongoing scrutiny underscores the critical need for transparency in clinical trials and the potential repercussions for companies that fail to meet their obligations to investors.

In light of the ongoing investigations, both law firms encourage investors to be vigilant and informed about their rights. The situation serves as a reminder of the delicate balance between innovation in the biotech sector and the accountability required to maintain investor trust. As Altimmune navigates these challenges, the outcomes of both the legal proceedings and the company's ongoing efforts in drug development will be closely watched by stakeholders in the biotechnology industry.